Stocktoria
Sionna Therapeutics, Inc. SION
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2025-02-07
Chart by TradingView
3/9
Piotroski F — financial health
17.07
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 |
|---|---|---|
| Financials | ||
| Operating income | -$89.0M | -$70.6M |
| Net income | -$75.3M | -$61.7M |
| Operating cash flow | -$66.3M | -$52.8M |
| Free cash flow | -$66.7M | -$52.8M |
| Total assets | $326.0M | $185.8M |
| Total liabilities | $19.1M | $19.1M |
| Shareholders' equity | $306.8M | -$163.7M |
| Ratios | ||
| Return on assets | -23.1% | -33.2% |
| Return on equity | -24.5% | 37.7% |
| Current ratio | 20.61 | 14.49 |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| Point72 Asset Management, L.P. | 136,549 | $5.5M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 17.07 (safe)
- Working capital / assets 0.705
- Retained earnings / assets -0.786
- EBIT / assets -0.273
- Equity / liabilities 16.048
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0002036042 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.